PITTSBURGH, July 2, 2024
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced
that the Antitrust Division of the U.S. Department of Justice
("DOJ") has advised that it no longer considers Mylan, and its
former President, Rajiv Malik, a
subject of its antitrust investigation in the generic drug
industry. The Civil Division of the DOJ has also informed
the Company that it does not expect to take any further
actions in connection with a civil investigative demand related to
the pricing and sales of generic drug products.
This outcome affirms the Company's longstanding position, which
it has consistently maintained and asserted, for many years, that
Mylan investigated these allegations thoroughly and found no
evidence of wrongdoing on the part of Mylan or its
employees.
The Company is pleased to put these DOJ investigations behind it
and will continue to move forward to vigorously defend itself
against the remaining civil lawsuits pertaining to these matters.
Please refer to Viatris' Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024 for more
information regarding these drug pricing matters.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global
healthcare company uniquely positioned to bridge the traditional
divide between generics and brands, combining the best of both to
more holistically address healthcare needs globally. With a mission
to empower people worldwide to live healthier at every stage of
life, we provide access at scale, currently supplying high-quality
medicines to approximately 1 billion patients around the world
annually and touching all of life's moments, from birth to the end
of life, acute conditions to chronic diseases. With our
exceptionally extensive and diverse portfolio of medicines, a
one-of-a-kind global supply chain designed to reach more people
when and where they need them, and the scientific expertise to
address some of the world's most enduring health challenges, access
takes on deep meaning at Viatris. We are headquartered in the U.S.,
with global centers in Pittsburgh,
Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
LinkedIn, Instagram, YouTube and X (formerly Twitter).
Forward-Looking Statements
This statement includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements about the outcome of
investigations and litigation and that the Company is pleased to
put these DOJ investigations behind it and will continue to move
forward to vigorously defend itself against the remaining civil
lawsuits pertaining to these matters. Because forward-looking
statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to: actions and decisions of healthcare and pharmaceutical
regulators; changes in healthcare and pharmaceutical laws and
regulations in the U.S. and abroad; any regulatory, legal or other
impediments to Viatris' ability to bring new products to market,
including but not limited to "at-risk" launches; Viatris' or its
partners' ability to develop, manufacture, and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings, and the impact of any such proceedings; the
possibility that Viatris may be unable to realize the intended
benefits of, or achieve the intended goals or outlooks with respect
to, its strategic initiatives; the possibility that Viatris may be
unable to achieve intended or expected benefits, goals, outlooks,
synergies, growth opportunities and operating efficiencies in
connection with divestitures, acquisitions, other transactions or
restructuring programs, within the expected timeframes or at all;
goodwill or impairment charges or other losses related to the
divestiture or sale of businesses or assets; Viatris' failure to
achieve expected or targeted future financial and operating
performance and results; the potential impact of public health
outbreaks, epidemics and pandemics; any significant breach of data
security or data privacy or disruptions to our information
technology systems; risks associated with international operations;
the ability to protect intellectual property and preserve
intellectual property rights; changes in third-party relationships;
the effect of any changes in Viatris' or its partners' customer and
supplier relationships and customer purchasing patterns; the
impacts of competition; changes in the economic and financial
conditions of Viatris or its partners; uncertainties and matters
beyond the control of management, including general economic
conditions, inflation and exchange rates; failure to execute stock
repurchases consistent with current expectations; stock price
volatility; and the other risks described in Viatris' filings with
the Securities and Exchange Commission (SEC). Viatris routinely
uses its website as a means of disclosing material information to
the public in a broad, non-exclusionary manner for purposes of the
SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no
obligation to update these statements for revisions or changes
after the date of this statement other than as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/us-department-of-justice-informs-viatris-that-it-no-longer-considers-mylan-a-subject-of-generic-drug-industry-antitrust-investigation-302187520.html
SOURCE Viatris Inc.